BioPharmSignal logoBioPharmSignal

Biotech News

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology (KURA)Kura OncologyConference / presentation

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Bank of America Securities 2026 Healthcare Conference.

Open original release

Related news

KURAKura Oncology2026-05-12 13:40 EST

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

KURAKura Oncology2026-06-02 12:32 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

BMYBMYBristol-Myers Squibb Company2026-05-06 10:59 EST

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-05-27 10:59 EST

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ERASErasca2026-05-06 12:00 EST

Erasca to Present at the Bank of America Securities Health Care Conference

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

View all latest news

Kura Oncology

Kura Oncology is a precision-oncology company focused on genetically defined cancers and targeted therapies. Its pipeline is centered on kinase biology and oncology differentiation.

Recent company news

KURAKura Oncology2026-06-03 10:53 EST

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

KURAKura Oncology2026-06-02 12:32 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

KURAKura Oncology2026-05-26 10:02 EST

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

KURAKura Oncology2026-05-19 20:02 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

KURAKura Oncology2026-05-12 20:02 EST

Kura Oncology Reports First Quarter 2026 Financial Results

Stock data

Close
10.15 USD
Market cap
796.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States